Distinguishing pathological neurodegeneration from normal biological aging is a fundamental challenge in preclinical neuroscience. Presented at AD/PD 2023 in Gothenburg, this poster — developed in collaboration with Sylics and VU University Amsterdam — establishes a novel method for discriminating neurodegenerative phenotypes from healthy aging using automated home-cage behavior analysis.
Le comportement spontané a été évalué de manière systématique pendant 2,5 jours à l’aide de 58 paramètres, dansdes cages PhenoTyper™ équipées du logiciel AHCODA™. Une analyse en composantes principales (ACP) portant sur plusieurs modèles murins de neurodégénérescence — notamment des modèles de la maladie d’Alzheimer et de tauopathie — a révélé des signatures comportementales spécifiques à chaque modèle, clairement distinguables du vieillissement naturel, avant même l’apparition de la physiopathologie classique de la maladie. Cette plateforme offre un outil sensible et indépendant de toute hypothèse permettant de caractériser les signes comportementaux caractéristiques de la neurodégénérescence et de tester de nouveaux traitements thérapeutiques chez des animaux en liberté de mouvement.
| Conference | AD/PD™ 2023 — International Conference on Alzheimer’s and Parkinson’s Diseases |
| Dates | March 28–April 1, 2023 |
| Location | Gothenburg, Sweden |
| Authors | Thomas Vogels¹², Bastijn Koopmans¹², Joshua Obermayer¹, Sabine Spijker³, Ronald E. van Kesteren³, Matthijs Verhage⁴⁵, August B. Smit³, Maarten Loos¹² |
| Affiliation | ¹Sylics (Synaptologics BV), Bilthoven; ²InnoSer BV, Leiden; ³Dept. Molecular & Cellular Neurobiology, CNCR, Amsterdam Neuroscience, VU University Amsterdam; ⁴Dept. Functional Genomics, CNCR, VU University Amsterdam; ⁵Dept. Clinical Genetics, VU Medical Center, Amsterdam |
| Collaboration | Sylics (Synaptologics BV); VU University Amsterdam — Center for Neurogenomics and Cognitive Research (CNCR) |
Résumé
Aging is the most common risk factor for Alzheimer’s disease and most other neurodegenerative disorders. Neurodegenerative diseases and natural healthy aging both show gradual deterioration in memory, cognition, and circadian rhythm. Studying features that separate neurodegenerative phenotypes from biological aging allows deeper understanding of disease pathophysiology and its potential treatments. Here, we establish a novel method to investigate complex patterns of spontaneous behavior to identify hallmarks of neurodegeneration, allowing its discrimination from natural healthy aging.
We performed systematic analysis of spontaneous home-cage behavior over 2.5 days (3 dark phases, 2 light phases) in widely used mouse models for neurodegenerative diseases at different ages. Mice were tested for 58 behavioral parameters in automated PhenoTyper™ home-cages, further analyzed using AHCODA™ software. Mutant mice were compared to wildtype littermates; compound-treated mice were compared to vehicle controls. Principal component analysis (PCA) was performed using R (FactoMineR package; 58 parameters).
PCA identified four behavioral clusters: activity during the light phase, activity during the dark phase, dark/light behavior change, and long sheltering/resting behavior. Different Aβ- and tau-related transgenic lines showed distinct phenotypes, with phenotypes generally becoming more pronounced at later timepoints. Natural aging mice showed a clear age-related progression clearly discriminable from neurodegenerative disease models.
Home-cage behavioral parameters are highly sensitive markers of neurodegenerative disease, detectable before classical pathophysiology emerges, and clearly distinguishable from normal aging. This approach allows discrimination between disease-carrying mutants, compound-induced models, and naturally aging mice — providing a platform to verify treatment efficacy in freely moving animals.

![Neurosciences translationnelles : profilage longitudinal complet des souris femelles et mâles porteurs de la mutation Tau[P301S]](https://www.innoserlaboratories.com/wp-content/uploads/2026/06/Female-TauP301S-mice-show-early-spontaneous-hyperactivity-in-automated-home-cages-PhenoTyperTM-229375_1080x323.png)

![Modèle murin Tau[P301S] dont la sensibilité au composé a été démontrée, destiné à la validation préclinique du concept](https://www.innoserlaboratories.com/wp-content/uploads/2026/03/Proven-Compound-susceptible-TauP301S-mouse-model-for-preclinical-proof-of-concept--1080x675.png)



![Neurosciences translationnelles : profilage longitudinal complet des souris femelles et mâles porteurs de la mutation Tau[P301S]](https://www.innoserlaboratories.com/wp-content/uploads/2026/06/Female-TauP301S-mice-show-early-spontaneous-hyperactivity-in-automated-home-cages-PhenoTyperTM-229375_400x250.png)
